Skip to main content

Table 1 Clinical groups for first-line treatment stratification

From: Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature

group clinical presentation
0 clearly R0-resectable liver and/or lung metastases
1 unresectable liver and/or lung metastasis potentially resectable after downsizing, comorbidities allowing surgery
2 multiple metastasis, rapid progression, risk of rapid deterioration, unlikely to become resectable
3 never resectable and no symptoms or risk of deterioration